Day: May 12, 2022

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will host a virtual key opinion leader (KOL) event, to discuss highlights from its presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting as well as its solid tumor program on Thursday, May 19, 2022, at 4:30 p.m. ET. The event will provide an in-depth review of the oral and poster presentations related to solid tumor TCR-T therapy candidates, TSC-200-A02 for HPV16, and TSC-204-C07 for MAGE-A1, as well as TScan’s approach to potentially overcome antigen heterogeneity and HLA loss with multiplexed TCR-T....

Completes debt transaction improving liquidity Q3 fiscal 2022 comparable store sales increased 0.6% versus Q3 fiscal 2021             DALLAS, May 12, 2022 (GLOBE NEWSWIRE) — Tuesday Morning Corporation (NASDAQ: TUEM), a leading off-price retailer of home goods and décor, today announced its results for the third quarter of fiscal 2022 ended April 2, 2022.   Fred Hand, Chief Executive Officer, stated, “We are very pleased to announce the completion of a debt transaction that results in a number of benefits including improved liquidity, and a $5 million reduction on our term loan.” Mr. Hand, continued, “Our comparable store sales increase through February was in line with our expectations contemplated in our original guidance. While our guidance assumed that March would be difficult due to the Easter shift and lapping stimulus,...

IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) — CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will debut its Office-Based, MR/US Fusion-Guided, TRANBERG® Thermal Therapy System for high precision, focal laser ablation of soft tissue, such as prostate cancer tumors, at the upcoming AUA 2022 Conference being held May 13-16, 2022 in New Orleans. The system is designed to work with multiple MR/US fusion image guidance systems for precise and accurate ablation in a minimally invasive setting, while preserving healthy prostate tissue. Focal therapies generally produce few side effects, such as erectile dysfunction and urinary incontinence. CLS Americas will be located in Booth #364. In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for...

SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in the following upcoming investor conferences: In-Person ConferencesJefferies Global Healthcare Conference: Adagene will make a live Fireside Chat presentation on Wednesday, June 8 at 4:30 p.m. Eastern Time (US). The presentation will be webcast and a replay available in the Investors section of the company’s website for at least 30 days. Management will also participate in one-on-one investor meetings at the conference to be held in New York, the United States.        Goldman Sachs Annual Global Healthcare Conference: Adagene will participate in one-on-one investor...

CHICAGO, May 12, 2022 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial real estate finance company, today announced its results for the first quarter ended March 31, 2022. John Mazarakis, Executive Chairman of Chicago Atlantic, noted, “The cannabis industry is one of the few sectors today that presents returns more correlated to regulatory milestones than the overall economic or interest rate environment. With a pipeline of $911 million in potential fundings, we continue to benefit from cannabis operators in our targeted limited-license states that are seeking debt capital to invest in accretive expansion plans to meet accelerating demand.” Tony Cappell, Chief Executive Officer of Chicago Atlantic, added, “We have maintained our strong start to the...

Updated financial guidance reflects strong Q1 performance and business momentum Practice Collections +63.3% compared to 1Q’21 Implemented Providers +27.3% compared to 1Q’21 Value-Based Care Attributed Lives +17.6% compared to 1Q’21ARLINGTON, Va., May 12, 2022 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2022. Total revenue for the first quarter of 2022 was $313.8 million, compared to total revenue of $213.6 million for the prior year first quarter (+46.9%). Operating loss for the first quarter of 2022 was $11.5 million, compared to operating income of $7.9 million for the prior year first quarter. Net loss for the first quarter of 2022 was $17.5 million, or a loss of $0.16 per share, compared to net income of $5.4 million, or $0.06 per share,...

UPPSALA, Sweden, May 12, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter of 2022. HighlightsFirst quarter 2022 revenue totaled $22.7 million, representing year over year growth of 66% on a reported basis and 72% on a constant currency adjusted like-for-like basis First quarter cumulative Explore customer installations reached 27, with 9 additional Signature Q100 placements Explore revenue of $15.7 million accounted for 69% of total first quarter revenue, with Explore Kit revenue totaling $2.1 million, or 13% of total Explore revenue First quarter kits revenue and analysis services revenue represented 18% and 73% of total revenue, respectively First quarter 2022 adjusted EBITDA was ($9.1) million, with a net loss of ($12.2) million; compared...

This first ever at-home COVID-19 and flu test is designed to allow individuals to differentiate between the infections and seek appropriate treatment within 30 minutes from home EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) — Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced today that it has submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) for its COVID-19 & Flu test. The request is for prescription at-home use of the PCR-quality test for those with suspected COVID-19 or Influenza. Lucira is seeking FDA authorization before this upcoming fall and winter, when SARS-CoV-2 and influenza viruses are likely to...